Prazosin displays anticancer activity against human prostate cancers: Targeting DNA and cell cycle

Neoplasia

Volumn 9, Issue 10, 2007, Pages 830-839

  Lin, Ssu Chia ^a   Chueh, Shih Chieh ^b   Hsiao, Che Jen ^c   Li, Tsia Kun ^d   Chen, Tzu Hsuan ^a   Liao, Cho Hwa ^a   Lyu, Ping Chiang ^c   Guh, Jih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cdc25c; Cell cycle; DNA damage; Mitochondria involved apoptosis; Prazosin

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE; DOXAZOSIN; PHENTOLAMINE; PRAZOSIN; PROTEIN TYROSINE PHOSPHATASE; SERINE; TAMSULOSIN; TERAZOSIN; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 35448965498     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07475     Document Type: Article

References (36)

1. Kyprianou N, English HF, and Isaacs JT (1990). Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50, 3748-3753.
2. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, and Bamias A (2005). Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology 65, 126-130.
3. Martel CL, Gumerlock PH, Meyers FJ, and Lara PN (2003). Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29, 171-187.
4. Angelucci A, Valentini A, Millimaggi D, Gravina GL, Miano R, Dolo V, Vicentini C, Bologna M, Federici G, and Bernardini S (2006). Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs 17, 1141-1150.
5. Chiang PC, Kung FL, Huang DM, Li TK, Fan JR, Pan SL, Shen YC, and Guh JH (2006). Induction of Fas clustering and apoptosis by coral prostanoid in human hormone-resistant prostate cancer cells. Eur J Pharmacol 542, 22-30.
6. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, and Sakai T (2006). The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor - related apoptosis-inducing ligand. Mol Cancer Ther 5, 945-951.
7. Ramaswamy B and Puhalla S (2006). Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barcelona) 42, 265-279.
8. Zhou J, Liu M, Aneja R, Chandra R, and Joshi HC (2004). Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012. Biochem Pharmacol 68, 2435-2441.
9. Wendt J, von Haefen C, Hemmati P, Belka C, Dorken B, and Daniel PT (2005). TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 24, 4052-4064.
10. Lu PH, Kung FL, Kuo SC, Chueh SC, and Guh JH (2006). Investigation of anti-tumor mechanisms of K2154: characterization of tubulin isotypes, mitotic arrest and apoptotic machinery. Naunyn Schmiedeberg's Arch Pharmacol 374, 223-233.
11. Hu H, Jiang C, Schuster T, Li GX, Daniel PT, and Lu J (2006). Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax - mediated activation of mitochondrial pathway. Mol Cancer Ther 5, 1873-1882.
12. 1-adrenoceptor - independent action. Cancer Res 62, 597-602.
13. Tahmatzopoulos A, Rowland RG, and Kyprianou N (2004). The role of α-blockers in the management of prostate cancer. Expert Opin Pharmacother 5, 1279-1285.
14. 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signaling and I kappa B α induction. Br J Cancer 88, 1615-1621.
15. 1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem 47, 4453-4462.
16. Garrison JB and Kyprianou N (2006). Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 66, 464-472.
17. Chiang CF, Son EL, and Wu GJ (2005). Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. Prostate 64, 408-418.
18. Walden PD, Globina Y, and Nieder A (2004). Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase. Urol Res 32, 261-265.
19. Castedo M, Perfettini JL, Roumier T, and Kroemer G (2002). Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9, 1287-1293.
20. Graves PR, Lovly CM, Uy GL, and Piwnica-Worms H (2001). Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 20, 1839-1851.
21. Karlsson-Rosenthal C and Millar JB (2006). Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 16, 285-292.
22. Bruneel A, Labas V, Mailloux A, Sharma S, Royer N, Vinh J, Pernet P, Vaubourdolle M, and Baudin B (2005). Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis. Proteomics 5, 3876-3884.
23. Szegezdi E, Logue SE, Gorman AM, and Samali A (2006). Mediators of endoplasmic reticulum stress - induced apoptosis. EMBO Rep 7, 880-885.
24. Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, and Navakauskiene R (2006). The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol 549, 9-18.
25. Jeggo PA and Lobrich M (2006). Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability. DNA Repair (Amsterdam) 5, 1192-1198.
26. Touny LH and Banerjee PP (2006). Identification of both Myt-1 and Wee-1 as necessary mediators of the p21-independent inactivation of the cdc-2/cyclin B1 complex and growth inhibition of TRAMP cancer cells by genistein. Prostate 66, 1542-1555.
27. Nilsson I and Hoffmann I (2000). Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 4, 107-114.
28. Shiah HS, Lee WS, Juang SH, Hong PC, Lung CC, Chang CJ, Chou KM, and Chang JY (2007). Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036. Biochem Pharmacol 73, 610-619.
29. Wang LG, Liu XM, Kreis W, and Budman DR (1999). The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44, 355-361.
30. Sordet O, Khan QA, Kohn KW, and Pommier Y (2003). Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents 3, 271-290.
31. Caruso F, Villa R, Rossi M, Pettinari C, Paduano F, Pennati M, Daidone MG, and Zaffaroni N (2007). Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3- bis(diphenylphosphino) propanegold(I) in melanoma cell lines. Biochem Pharmacol 73, 773-781.
32. Michels J, Johnson PW, and Packham G (2005). Mcl-1. Int J Biochem Cell Biol 37, 267-271.
33. Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, and Auberger P (2004). Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 23, 7863-7873.
34. Condorelli F, Salomoni P, Cotteret S, Cesi V, Srinivasula SM, Alnemri ES, and Calabretta B (2001). Caspase cleavage enhances the apoptosis-inducing effects of BAD. Mol Cell Biol 21, 3025-3036.
35. Ward MW, Rehm M, Duessmann H, Kacmar S, Concannon CG, and Prehn JH (2006). Real time single cell analysis of Bid cleavage and Bid translocation during caspase-dependent and neuronal caspase-independent apoptosis. J Biol Chem 281, 5837-5844.
36. Antonello A, Hrelia P, Leonardi A, Marucci G, Rosini M, Tarozzi A, Tumiatti V, and Melchiorre C (2005). Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds. J Med Chem 48, 28-31.